Umoja hopes to transform the future of cancer treatment by combining a deep understanding of immune physiology and genetic engineering with the most advanced, integrated cellular immunotherapy platform for cancer treatment currently under development.
Our treatment approach retools a patient’s immune system in vivo to direct potent anti-cancer immune cells to a patient’s tumor, augmenting the body’s natural mechanisms for fighting cancer.
Personalized therapy without complex and costly manufacturing
No lengthy treatment timelines
A treatment that is accessible to patients everywhere
Who We Are
Umoja is driven by a bold and unified vision to transform cancer treatment and improve quality of life. We are a diverse group of drug development experts, scientists and researchers that are skilled, passionate, persistent, and relentlessly committed to finding a way to break through the current challenges encountered in immuno-oncology.
We also strive to foster a distinct culture that celebrates every team member’s diverse set of skills and contributions. We believe our collective strengths and unique perspectives are what make Umoja a great place to work.
Senior Leadership
Andy Scharenberg, M.D.
Co-founder and CEO
Ryan Crisman, Ph.D.
Co-founder and CTO
Tim Gardner, MBA
EVP, Strategy and Business Development
Board of Directors
Andy Scharenberg, M.D.
Co-founder, Umoja
Luke Evnin, Ph.D.
MPM Capital
Phil Low, Ph.D.
Co-founder, Umoja; Purdue University
John Hamer, Ph.D.
DCVC Bio
Anna French, Ph.D.
Qiming Venture Partners
Advisory Board
Michael Jensen, M.D.
Co-founder, Umoja; Seattle Children's Hospital
Rimas Orentas, Ph.D.
Ben Towne Center for Childhood Cancer
Hans-Peter Kiem, M.D., Ph.D.
Fred Hutch Endowed Chair for Cell and Gene Therapy
Franklin M. Berger, CFA
Co-founder and Managing Director, FMB Research
We are a young but fast-growing company. And we’re looking for passionate, driven people inspired to help people living with cancer. If Umoja sounds like a place for you, we’d love to hear from you!
Latest News
Umoja Biopharma Launches with $53M Series A Financing to Develop Fully Integrated, Scalable, In Vivo Immunotherapy Platform
Umoja’s platform addresses key limitations of existing engineered immunotherapies.
Company backed by prominent life science investors MPM Capital, DCVC Bio and Qiming Venture Partners USA and led by an experienced team of scientist/entrepreneurs.